JP4248251B2 - Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト - Google Patents

Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト Download PDF

Info

Publication number
JP4248251B2
JP4248251B2 JP2002577819A JP2002577819A JP4248251B2 JP 4248251 B2 JP4248251 B2 JP 4248251B2 JP 2002577819 A JP2002577819 A JP 2002577819A JP 2002577819 A JP2002577819 A JP 2002577819A JP 4248251 B2 JP4248251 B2 JP 4248251B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002577819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525157A (ja
JP2004525157A5 (enExample
Inventor
マイケル ダブリュー． ミラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004525157A publication Critical patent/JP2004525157A/ja
Publication of JP2004525157A5 publication Critical patent/JP2004525157A5/ja
Application granted granted Critical
Publication of JP4248251B2 publication Critical patent/JP4248251B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2002577819A 2001-03-29 2002-03-27 Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト Expired - Fee Related JP4248251B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29
PCT/US2002/009491 WO2002079194A1 (en) 2001-03-29 2002-03-27 Ccr5 antagonists useful for treating aids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007279663A Division JP2008074862A (ja) 2001-03-29 2007-10-26 Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト

Publications (3)

Publication Number Publication Date
JP2004525157A JP2004525157A (ja) 2004-08-19
JP2004525157A5 JP2004525157A5 (enExample) 2006-01-05
JP4248251B2 true JP4248251B2 (ja) 2009-04-02

Family

ID=23070981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002577819A Expired - Fee Related JP4248251B2 (ja) 2001-03-29 2002-03-27 Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト
JP2007279663A Withdrawn JP2008074862A (ja) 2001-03-29 2007-10-26 Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007279663A Withdrawn JP2008074862A (ja) 2001-03-29 2007-10-26 Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト

Country Status (29)

Country Link
US (5) US6720325B2 (enExample)
EP (2) EP1591444B1 (enExample)
JP (2) JP4248251B2 (enExample)
KR (1) KR100613528B1 (enExample)
CN (1) CN100519554C (enExample)
AR (1) AR033452A1 (enExample)
AT (2) ATE466009T1 (enExample)
AU (1) AU2002255947B8 (enExample)
BR (1) BR0208398A (enExample)
CA (1) CA2442227C (enExample)
CZ (1) CZ20032636A3 (enExample)
DE (2) DE60204951T2 (enExample)
DK (1) DK1373256T3 (enExample)
ES (2) ES2342942T3 (enExample)
HU (1) HUP0400349A3 (enExample)
IL (1) IL157551A0 (enExample)
MX (1) MXPA03008853A (enExample)
MY (1) MY128609A (enExample)
NO (1) NO326349B1 (enExample)
NZ (1) NZ527768A (enExample)
PE (1) PE20020996A1 (enExample)
PL (1) PL364560A1 (enExample)
PT (1) PT1373256E (enExample)
RU (1) RU2316553C2 (enExample)
SI (1) SI1373256T1 (enExample)
SK (1) SK287521B6 (enExample)
TW (1) TWI237638B (enExample)
WO (1) WO2002079194A1 (enExample)
ZA (1) ZA200307474B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008074862A (ja) * 2001-03-29 2008-04-03 Schering Corp Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209736T2 (de) 2001-07-02 2006-11-02 Astrazeneca Ab Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7132539B2 (en) * 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
WO2004055011A1 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
AU2004285051A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
EP1725235B1 (en) * 2004-02-05 2009-04-15 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
ES2431524T3 (es) * 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101133048A (zh) * 2005-01-06 2008-02-27 先灵公司 哌嗪化合物的药用盐制备
WO2006074270A2 (en) * 2005-01-06 2006-07-13 Schering Corporation Synthesis of ccr5 receptor antagonists
MX2007010257A (es) 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperidina utiles como inhibidores de receptores de quimiocinas.
KR20070107085A (ko) * 2005-02-23 2007-11-06 쉐링 코포레이션 케모카인 수용체의 억제제로서 유용한 피페리디닐 피페라진유도체
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
EP2125733A1 (en) * 2006-12-22 2009-12-02 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DE69623485T2 (de) 1995-06-07 2003-01-09 Kimberly-Clark Worldwide, Inc. Inhibierung von exoprotein in absorbierenden produkten
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
EP1003514A4 (en) 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
SK286641B6 (sk) 1999-05-04 2009-03-05 Schering Corporation Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
PL203117B1 (pl) * 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
ATE466009T1 (de) * 2001-03-29 2010-05-15 Schering Corp Ccr5 antagonisten verwendbar für die behandlung von aids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008074862A (ja) * 2001-03-29 2008-04-03 Schering Corp Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト

Also Published As

Publication number Publication date
CN1547580A (zh) 2004-11-17
MXPA03008853A (es) 2003-12-04
JP2004525157A (ja) 2004-08-19
DK1373256T3 (da) 2005-10-10
US7008946B2 (en) 2006-03-07
SK11962003A3 (sk) 2004-03-02
US20040157854A1 (en) 2004-08-12
US7098213B2 (en) 2006-08-29
WO2002079194A1 (en) 2002-10-10
HK1083505A1 (en) 2006-07-07
SI1373256T1 (sl) 2005-12-31
ATE466009T1 (de) 2010-05-15
ES2242856T3 (es) 2005-11-16
HUP0400349A2 (hu) 2004-12-28
DE60204951T2 (de) 2006-05-11
AU2002255947B2 (en) 2005-10-27
KR20030083014A (ko) 2003-10-23
ATE299139T1 (de) 2005-07-15
US6720325B2 (en) 2004-04-13
US6900211B2 (en) 2005-05-31
DE60204951D1 (de) 2005-08-11
TWI237638B (en) 2005-08-11
EP1373256A1 (en) 2004-01-02
PL364560A1 (en) 2004-12-13
PT1373256E (pt) 2005-11-30
HUP0400349A3 (en) 2010-03-29
JP2008074862A (ja) 2008-04-03
AR033452A1 (es) 2003-12-17
BR0208398A (pt) 2004-06-15
EP1591444A1 (en) 2005-11-02
MY128609A (en) 2007-02-28
HK1057363A1 (en) 2004-04-02
RU2316553C2 (ru) 2008-02-10
NO326349B1 (no) 2008-11-17
EP1373256B1 (en) 2005-07-06
PE20020996A1 (es) 2002-11-01
DE60236218D1 (de) 2010-06-10
ES2342942T3 (es) 2010-07-19
SK287521B6 (sk) 2010-12-07
RU2003131879A (ru) 2005-05-10
NO20034311D0 (no) 2003-09-26
US20060063771A1 (en) 2006-03-23
CA2442227A1 (en) 2002-10-10
ZA200307474B (en) 2004-12-24
NO20034311L (no) 2003-11-26
IL157551A0 (en) 2004-03-28
US7060701B2 (en) 2006-06-13
AU2002255947B8 (en) 2005-11-17
EP1591444B1 (en) 2010-04-28
US20050143390A1 (en) 2005-06-30
KR100613528B1 (ko) 2006-08-16
CN100519554C (zh) 2009-07-29
CZ20032636A3 (cs) 2003-12-17
CA2442227C (en) 2008-10-28
US20030008877A1 (en) 2003-01-09
US20050059666A1 (en) 2005-03-17
NZ527768A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
JP2008074862A (ja) Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト
JP3894729B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
JP4223950B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
JP4303969B2 (ja) Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン
JP4589728B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
JP2009512705A (ja) Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
US20070203149A1 (en) Ccr5 antagonists useful for treating hiv
HK1057363B (en) Ccr5 antagonists useful for treating aids
HK1083505B (en) Ccr5 antagonists useful for treating aids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090106

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120123

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees